AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Summary

This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.

Timeline

Start

2024-01-16

Primary completion

2028-01-01

Completion

2028-01-01

Publications

• Damato A, Maglietta G, Antonuzzo L, Berardi R, Buonadonna A, Brighi N, Cinieri S, Di Micco C, Gelsomino F, Grossi F, Martinelli E, Cesario S, Pusceddu S, Spada F, Iachetta F, Gervasi E, Ciardiello G, Normanno N, Pinto C. Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). BMC Cancer. 2025 Nov 12;25(1):1763. doi: 10.1186/s12885-025-15112-w.

Drugs

Indications